

Travis A Gerke, ScD  
Curriculum Vitae  
Prepared November 6, 2023

### Current Position

Director of Data Science

The Prostate Cancer Clinical Trials Consortium  
1275 York Ave  
New York, NY 10065

Email: [gerket@mskcc.org](mailto:gerket@mskcc.org)

### Education

2007–2009 B.A. (Mathematics), University of Florida, Gainesville, FL  
2007–2009 B.S. (Statistics), University of Florida, Gainesville, FL  
2009–2011 A.M. (Biostatistics), Harvard University, Cambridge, MA  
2012–2014 Sc.D. (Epidemiology), Harvard School of Public Health, Boston, MA

### Previous Academic Appointments and Employment

2008–2009 Research Assistant, Rehabilitation Outcomes Research Center, Department of Veterans Affairs, Gainesville, FL  
2011–2012 Statistician I, Department of Epidemiology, Harvard School of Public Health, Boston, MA  
2012–2013 Graduate Research Assistant in Biostatistics, Dana-Farber Cancer Institute, Boston, MA  
2012–2014 Graduate Research Assistant in Cancer Epidemiology, Harvard School of Public Health, Boston, MA  
2014–2016 Assistant Professor (Tenure Track), Department of Epidemiology, College of Medicine and College of Public Health and Health Professions, University of Florida, Gainesville, FL  
2014–2020 Visiting Scientist, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA  
2016–2021 Assistant Professor, Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL  
2016–2020 Assistant Member (Tenure Track), Department of Cancer Epidemiology, Moffitt Cancer Center & Research Institute, Tampa, FL  
2020–2021 Health Informatics Director / Scientific Director of Collaborative Data Services, Moffitt Cancer Center & Research Institute, Tampa, FL

### Teaching

#### *University Courses*

2008–2009 Teaching Assistant, Statistics 2023: Introduction to Statistics, Department of Statistics, University of Florida  
2011 Lab Instructor, Biostatistics 210: The Analysis of Rates and Proportions, Department of Biostatistics, Harvard School of Public Health  
2013 Instructor, Introduction to Biostatistics and Statistical Programming, Summer Program in Epidemiology, Department of Epidemiology, Harvard School of Public Health  
2015 Instructor, Epidemiology Methods II (PHC 6011), Department of Epidemiology, University of Florida  
2016 Instructor, Measurement in Epidemiology and Outcomes Research (PHC 6711), Department

of Epidemiology, University of Florida

### *Other Courses*

2017–2021 Faculty/Instructor, AACR Integrative Molecular Epidemiology Workshop: Bridging Cancer Biology and Precision Medicine, Boston, MA. Sections taught: Publicly Available Online Genomics and ‘Omics Resources; Bioinformatics Toolkits for Functional Analysis; Precision Medicine: Predictive Modeling from High-Throughput Results; Data Sharing and Organization

### *Invited Lectures*

2016 Leveraging big data resources to understand public health disparities. Translational Research and Therapeutics: Bench, Bedside, Community, & Policy; University of Florida course GMS 7593.  
2017 Fundamentals of integrative molecular epidemiology. Quantitative Genomics and Genetics; University of South Florida course PHC 6934.  
2018 Prostate cancer epidemiology. Cancer Epidemiology; University of South Florida course PHC 6007.

### Training Experience

#### *Doctoral dissertation committee membership*

2014–2017 Molly Buchanan, Department of Sociology and Criminology & Law, University of Florida  
2015 Zahra Shekarkhar, Department of Sociology and Criminology & Law, University of Florida  
2015–2016 Abenaa Acheampong, Department of Epidemiology, University of Florida  
2015–2017 Yuanfang Ren, Department of Computer & Information Science & Engineering, University of Florida

#### *Master’s thesis committee membership*

2014–2015 Fangyu Su, Department of Epidemiology, University of Florida (Chair)  
2014–2015 Chelsea Lutz, Department of Epidemiology, University of Florida (Chair)  
2014–2015 Chi Wang, Department of Epidemiology, University of Florida (Chair)  
2014–2015 Danmeng Li, Department of Epidemiology, University of Florida

### Honors and awards

2016 William R. Jones Most Valuable Mentor Award, Florida Education Fund McKnight Doctoral Fellowship Program

### Research support

#### Completed funding

#### *External grants*

|                 |   |
|-----------------|---|
| Grant #:        | P30 CA076292  |
| Name of PI:     | Sellers   |
| Dates:          | 02/18/1998 – 01/31/2022 (Dr. Gerke’s coverage: 01/01/2018 – 06/11/2021) |
| Funding Source: | National Cancer Institute   |
| Title:          | Moffitt Cancer Center Support Grant: Years 17–23                        |
| Funded Effort:  | 10%   |

|                 |  |
|-----------------|--|
| Role in Study:  | Co-I: Scientific Director of the Collaborative Data Services Core shared resource  |
| Direct Costs:   | \$7,999,091  |
| Award Amount:   | \$13,757,890   |
| Grant #:        | R21 CA234787   |
| Name of PI:     | Enderling/Gatenby  |
| Dates:          | 07/01/2019 – 06/30/2021 (Dr. Gerke's effort transferred on 05/17/2020)   |
| Funding Source: | NIH/NCI – R21  |
| Title:          | Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer  |
| Funded Effort:  | 5%   |
| Role in Study:  | Co-I: Lead biostatistician guiding appropriate design strategies for and implementation of prediction model development and validation                                 |
| Direct Costs:   | \$265,786  |
| Award Amount:   | \$422,386  |
| Grant #:        | PC181013   |
| Name of PI:     | Yamoah/Park/Rounbehler   |
| Dates:          | 08/01/2019 – 07/31/2022 (Dr. Gerke's effort transferred on 05/17/2020)   |
| Funding Source: | Department of Defense Health Disparities Research Award  |
| Title:          | Characterize the immune-oncologic profile of lethal prostate cancer in African American men and develop new therapeutic avenues of therapy for this patient population |
| Funded Effort:  | 5%   |
| Role in Study:  | Co-I: Lead biostatistician and data scientist, overseeing data management, quality control, and biostatistical analyses of gene expression and other biomarker data    |
| Direct Costs:   | \$999,963  |
| Award Amount:   | \$1,719,936  |
| Grant #:        | T2017-017  |
| Name of PI:     | Park/Yamoah  |
| Dates:          | 12/19/2017 – 11/01/2020 (Dr. Gerke's effort transferred on 05/17/2020)   |
| Funding Source: | V Foundation for Cancer Research   |
| Title:          | Genomic predictors of aggressive and lethal prostate cancer in African American men.   |
| Funded Effort:  | 5%   |
| Role in Study:  | Co-I: Quantitative epidemiologist providing direction on design and implementation strategies for biomarker discovery and validation                                   |
| Direct Costs:   | \$545,454  |
| Award Amount:   | \$600,000  |

#### *Internal grants*

|                 |   |
|-----------------|---|
| Name of PI:     | Gerke, Kahveci (co-PI)  |
| Dates:          | 02/15/2015 – 02/14/2016   |
| Funding Source: | UF Health Cancer Center Pilot Project Award                               |
| Title:          | Inferring the genetic architecture of gene expression in prostate cancer. |
| Funded Effort:  | 0%  |
| Role in Study:  | Co-PI   |
| Direct Costs:   | \$60,000  |
| Award Amount:   | \$60,000  |

|                 |   |
|-----------------|---|
| Name of PI:     | Gerke, Rollison (co-PI)   |
| Dates:          | 12/01/16 – 06/30/17   |
| Funding Source: | Moffitt Innovation Award  |
| Title:          | Machine learning approaches to identifying cancer recurrence from EMR data.                                     |
| Funded Effort:  | 0%  |
| Role in Study:  | PI  |
| Direct Costs:   | \$40,000  |
| Award Amount:   | \$40,000  |
|                 |   |
| Name of PI:     | Monteiro  |
| Dates:          | 07/01/2017 – 06/30/2018   |
| Funding Source: | Moffitt Cancer Center, Miles for Moffitt Award  |
| Title:          | Scaffold/Matrix Attachment Regions: structural genomic elements modulating cancer susceptibility.               |
| Funded Effort:  | 5%  |
| Role in Study:  | Co-I  |
| Direct Costs:   | \$100,000   |
| Award Amount:   | \$100,000   |
|                 |   |
| Name of PI:     | Chung/Anderson/Gerke  |
| Dates:          | 04/01/2018 – 01/31/2019   |
| Funding Source: | Moffitt Cancer Center Team Science Award  |
| Title:          | Precision medicine for thyroid nodules with indeterminate cytology.   |
| Funded Effort:  | 2%  |
| Role in Study:  | co-PI   |
| Direct Costs:   | \$100,000   |
| Award Amount:   | \$100,000   |
|                 |   |
| Name of PI:     | Berglund, Carvajal (co-PI)  |
| Dates:          | 04/01/2018 – 03/31/2019   |
| Funding Source: | Moffitt Cancer Center, Innovative Core Project Award  |
| Title:          | Complex cohort identification based on patient's timeline (CCIPT-View): an integrated view of a cancer patient. |
| Funded Effort:  | 1%  |
| Role in Study:  | Co-I  |
| Direct Costs:   | \$50,000  |
| Award Amount:   | \$50,000  |
|                 |   |
| Name of PI:     | Gerke   |
| Dates:          | 09/01/2018 – 08/31/2019   |
| Funding Source: | American Cancer Society - Institutional Research Grant  |
| Title:          | Leveraging big data towards an improved understanding of racial disparities in prostate cancer outcomes.        |
| Funded Effort:  | 5% (cost-shared)  |
| Role in Study:  | PI  |
| Direct Costs:   | \$30,000  |
| Award Amount:   | \$30,000  |
|                 |   |
| Grant #:        | 19011601  |
| Name of PI:     | Gerke/Aden-Buie   |
| Dates:          | 05/01/2019 – 04/30/2020   |

Funding Source: DPR Innovative Core Project  
 Title: DV<sup>3</sup>: A customer-driven framework for data spoke creation, access, and governance.  
 Funded Effort: 3%  
 Role in Study: PI  
 Direct Costs: \$50,000  
 Award Amount: \$50,000

Name of PI: Coghill  
 Dates: 02/01/2020 – 01/31/2021 (Dr. Gerke's effort transferred on 05/17/2020)  
 Funding Source: Moffitt Cancer Center, Miles for Moffitt Award  
 Title: Differences in prostate cancer molecular features by HIV status.  
 Funded Effort: 5%  
 Role in Study: Co-I  
 Direct Costs: \$100,000  
 Award Amount: \$100,000

#### *Contracts*

Name of PI: Gerke/Bird/Manini/Prosperi  
 Dates: 01/01/2016 – 12/31/2017  
 Funding Source: UF Cancer-Aging Collaborative Team Grant  
 Title: Endotype discovery in prostate cancer and multi-domain analysis of age-related comorbidities.  
 Funded Effort: 0%  
 Role in Study: Co-PI  
 Direct Costs: \$40,000  
 Award Amount: \$40,000

Grant #: W81XWH-18-1-0199  
 Name of PI: Kantoff  
 Dates: 09/30/2018 – 09/29/2021 (Dr. Gerke's effort transferred on 05/17/2020)  
 Funding Source: DoD/Memorial Sloan Kettering Cancer Center  
 Title: Mutational landscape of the Y chromosome and prostate cancer.  
 Funded Effort: 10%  
 Role in Study: PI, Subcontract: Lead epidemiologist and biostatistician towards biomarker discovery and validation  
 Direct Costs: \$45,964  
 Award Amount: \$79,058

Grant #: R21CA24167  
 Name of PI: Tyekucheva  
 Dates: 04/01/2020 – 03/31/2022 (Dr. Gerke's effort transferred on 05/17/2020)  
 Funding Source: NIH/NCI – R21, Dana Farber Cancer Institute  
 Title: Curated prostate cancer data for novel and reproducible prognostic modeling.  
 Funded Effort: 10%  
 Role in Study: Site PI: Lead data scientist for data coordination and quality control, as well as epidemiologic methods guidance  
 Direct Costs: \$89,864  
 Award Amount: \$154,566

## Patents

- 2017 Huttenhower C, **Gerke TA**, Sweeney C, Mucci L, Lee G, Börnigen D, Wang X, Tyekucheva S, Jordahl K. Compositions and methods for screening and identifying clinically aggressive prostate cancer. PCT/US2017/014362; WO2017127696A1.

## Dissertation

Title: Discovering and validating prognostic biomarkers in prostate cancer by focusing on population impact.

Defended: November 12, 2014, Harvard School of Public Health, Boston, MA

Committee: Lorelei Mucci (chair), Giovanni Parmigiani, Meir Stampfer, Christopher Sweeney

## Service at Moffitt Cancer Center

### *Administrative appointments*

- 2018– Scientific Director, Collaborative Data Services Core. 10% FTE.

### *Committees*

- 2016–2017 Member, Data Documentation and Management Best Practices Task Force. Monthly meetings; 4 hr/month commitment, 10 months term.
- 2017 Chair, Cancer Epidemiology Research Data Analyst Task Force. Monthly meetings; 5 hr/month commitment, 4 months term.
- 2017 Member, Unstructured Data Mining Advisory Group. Monthly meetings; 2 hr/month commitment, 5 months term.
- 2018 Member, Department of Cancer Epidemiology Website Redesign Task Force, Monthly meetings; 1 hr/month commitment, 3 months term.
- 2017–2021 Member, High Performance Computing Steering Committee. Monthly meetings; 1 hr/month commitment.
- 2017–2021 Planning Committee Member, The Biology of Cancer Health Disparities Seminar Series, Monthly meetings; 1 hr/month commitment.
- 2018–2021 Member, Total Cancer Care Strategic Operations Committee (TCC-SOC), Quarterly meetings; 1 hr/month commitment.
- 2018–2021 Member, Health and Research Informatics (HRI) Governance Committee, Biweekly meetings; 2 hr/month commitment.
- 2018–2021 Member, Data Sharing & Management Task Force, Monthly meetings; 2 hr/month commitment.
- 2019 Member, HRI Molecular Data Training Task Force, Monthly meetings; 2 hr/month commitment, 3 months term.
- 2019–2021 Member, Shared Resource Advisory Committee for the PRISM Core, 2–3 meetings per year + periodic scientific input and guidance; 1 hr/month commitment.

## Service at University of Florida

- 2015–2016 Co-chair, Graduate Admissions Committee, Department of Epidemiology
- 2015–2016 Member, Epidemiology Faculty Committee, Department of Epidemiology
- 2015–2016 Member, Seminar Committee, Department of Epidemiology
- 2015–2016 Member, Cancer Recruitment Committee, Department of Epidemiology
- 2015–2016 Member, Fundraising Committee, Department of Epidemiology
- 2015–2016 Member, TLI Advisory Committee, Clinical and Translational Science Institute

2015–2016 Consultant, Biostatistics, Epidemiology and Research Design Program (BERD), Clinical and Translational Science Institute

### Service to the Profession

2011–2013 IRB panel member, Brigham and Women’s Hospital, Boston, MA  
2014 Ad-hoc reviewer (1 manuscript): Cancer Medicine  
2016 Ad-hoc reviewer (2 manuscripts): Cancer Epidemiology, Biomarkers & Prevention; IEEE/ACM Transactions on Computational Biology and Bioinformatics  
2016 Member, Scientific Review Committee, The Science of Global Prostate Cancer Disparities Conference, Nov 9–12; Orlando, FL.  
2016 Session moderator, Personalized Medicine: From Bench to Bedside to Community; The Science of Global Prostate Cancer Disparities Conference, Nov 9–12; Orlando, FL.  
2017 Ad-hoc reviewer (10 manuscripts): Cancer Medicine (4); BMC Urology; Cancer Causes & Control; Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; IEEE/ACM Transactions on Computational Biology and Bioinformatics (2)  
2017 Ad-hoc grant reviewer, Genesis Oncology Trust, Research Project Grants Mechanism  
2015–2017 Co-leader, Computational Patho-Epidemiology Working Group, Transdisciplinary Prostate Cancer Partnership (ToPCaP), Boston, MA  
2018 Ad-hoc reviewer (10 manuscripts): Cancer Research; JNCI; JAMA Oncology (2); European Urology; IEEE/ACM Transactions on Computational Biology and Bioinformatics; Journal of Open Source Software (2); International Journal of Cancer; PeerJ  
2018 Ad-hoc grant reviewer: Cancer Research UK, Population Research Postdoctoral Fellowship Mechanism; University of Florida Informatics Institute (UFII) and Clinical Translational Institute (CTSI), Pilot Project Program  
2019 Ad-hoc reviewer (16 manuscripts): PeerJ; Cancer Epidemiology, Biomarkers & Prevention (4); Cancer Research; JNCI, CHEST (9)  
2019–2020 Member, Statistical Review Panel, CHEST Journal; 2–4 articles per month  
2019–2021 Member, Flatiron Health Academic Research Oversight Committee, Quarterly meetings; 1 hr/month commitment  
2019–2021 Executive Board Member, Florida Interdisciplinary Data Sciences Consortium (IDSC)  
2020 Ad-hoc reviewer: Cancer Epidemiology, Biomarkers & Prevention (2); CHEST  
2020 Core Team Member, Flatiron R Package Universe; 1 hr/month commitment  
2021 Ad-hoc reviewer: Cancer Epidemiology, Biomarkers & Prevention

### Service to the Community

2017–2020 Founding organizer, Tampa Bay R Users Group, Tampa, FL

### Professional association memberships

2011–2020 Active member, Transdisciplinary Prostate Cancer Partnership (ToPCaP), Boston, MA  
2014–2020 Active member, Prostate Cancer Transatlantic Consortium (CaPTC), Gainesville, FL  
2015–2020 Active member, American Association for Cancer Research (AACR)  
2017–2020 Active member, Molecular Epidemiology Working Group of the AACR (MEG/AACR)  
2019–2020 Active member, Society for Epidemiologic Research (SER)  
2019–2021 Active member, Cancer Informatics for Cancer Centers (Ci4CC)

### Peer-reviewed publications

*Underline denotes first/co-first and senior/co-senior*

1. **Gerke TA**, Randles RH. A method for resolving ties in asymptotic relative efficiency. Stat Probabil Lett 2010; 80:1065–1069.

2. Kachouie NN, **Gerke TA**, Huybers P, Schwartzman A. Nonparametric regression for estimation of spatiotemporal mountain glacier retreat from satellite images. *IEEE Trans Geosci Remote Sens* 2014; 53(3): 1135–1149.
3. Shui IM, Lindström S, Berndt SI, Campa D, **Gerke TA**, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Hoover R, Johansson M, Ma J, Navarro C, Overvad K, Siddiq A, Stampfer MJ, Stevens VL, Travis R, Trichopoulos D, Vineis P, Mucci LA, Yaeger M, Giovannucci EL, Kraft P. Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. *Eur Urol* 2014; 65(6): 1069–1075. PMID: 24411283. PMCID: PMC4006298.
4. Bismar TA, Alshalalfa M, Petersen LF, Teng LH, **Gerke TA**, Bakkar A, Al-Mami A, Liu S, Dolph M, Mucci LA, Alhaji R. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. *Brit J Urol Int* 2014; 113(2): 309–319. PMID: 24006850.
5. Penney KL, Sinnott JA, Tyekucheva S, **Gerke TA**, Shui IM, Kraft P, Sesso HD, Freedman M, Loda MF, Mucci LA, Stampfer MJ. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. *Cancer Epidemiol Biomarkers Prev* 2015; 24(1): 255–260. PMID: 25371445. PMCID: PMC4294966.
6. Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, **Gerke TA**, Albanes D, Black A, Berg CD, Bueno-de-Mesquita HB, Gapstur SM, Haiman C, Henderson B, Hoover R, Hunter DJ, Johansson M, Key TJ, Khaw K, Marchand L, Ma J, McCullough ML, Siddiq A, Stampfer M, Stram DO, Stevens VL, Trichopoulos D, Tumino R, Willett W, Ziegler RG, Kühn T, Barricarte A, Tjønneland A, Mucci LA, Giovannucci E, Kraft P. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. *Cancer* 2015; 121(12): 1949–1956. PMID: 25731953. PMCID: PMC4457645.
7. Sinnott JA, Rider JR, Carlsson J, **Gerke TA**, Tyekucheva S, Penney K, Sesso HD, Loda M, Parmigiani G, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson S, Andrén O. Molecular Differences in Transition Zone and Peripheral Zone Prostate Tumors. *Carcinogenesis* 2015; 36(6): 632–638. PMID: 25870172. PMCID: PMC4572920.
8. Rider JR, Fiorentino M, Kelly R, **Gerke TA**, Jordahl K, Sinnott JA, Giovannucci EL, Loda MF, Mucci LA, Finn S. Tumor expression of Adiponectin Receptor 2 and lethal prostate cancer. *Carcinogenesis* 2015; 36(6): 639–647. PMID: 25863129. PMCID: PMC4481603.
9. Terry RS, **Gerke TA**, Mason JB, Sorenson MD, Joseph JP, Dahm P, Su L. Postoperative rhabdomyolysis following robotic renal and adrenal surgery: a cautionary tale of compounding risk factors. *J Robotic Surg* 2015; 9(3): 195–200. PMID: 26531199.
10. Martin NE, **Gerke TA**, Sinnott JA, Stack EC, Andrén O, Andersson S, Johansson J, Fiorentino M, Finn S, Fedele G, Stampfer MJ, Kantoff PW, Mucci LA, Loda MF. Measuring PI3K activation: Clinicopathologic, immunohistochemical, and RNA expression analysis in prostate cancer. *Mol Cancer Res* 2015; 13(10): 1431–1440. PMID: 26124442. PMCID: PMC4618038.
11. **Gerke TA\***, Martin NE\*, Ding Z, Nuttall E, Stack EC, Giovannucci EL, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda MF, Mucci LA. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. *Prostate* 2015; 75(16): 1926–1933. PMID: 26469352. PMCID: PMC4738177.
12. Ahearn T, Pettersson A, Ebot EM, **Gerke TA**, Graff R, Morais CL, Hicks J, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer



- MJ, De Marzo AM, Mucci LA, Lotan TL. A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. *JNCI* 2015; 108(2): pii djv346. PMID: 26615022 PMCID: PMC4862436.
13. Conboy L, **Gerke TA**, Hsu KY, St John M, Goldstein M, Schnyer R. The effectiveness of individualized acupuncture protocols in the treatment of Gulf War Illness: A pragmatic randomized clinical trial. *PLoS One* 2016; 11(3): e0149161. PMID: 27031099. PMCID: PMC4816551.
  14. Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, **Gerke TA**, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K. Stress-related signaling pathways in lethal and non-lethal prostate cancer. *Clin Cancer Res* 2016; 22(3): 765–772. PMID: 26490316. PMCID: PMC4738177.
  15. Stopsack KH, **Gerke TA**, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson S, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol metabolism and lethal prostate cancer. *Cancer Res* 2016; 76(16): 4785–4790. PMID: 27325648. PMCID: PMC4987257.
  16. Preston MA, Batista JL, Carlsson SV, **Gerke TA**, Sjöberg DD, Dahl DM, Sesso H, Feldman AS, Gann PH, Vickers AJ, Mucci LA. Baseline prostate-specific antigen (PSA) levels in midlife predict lethal prostate cancer. *J Clin Oncol* 2016; 34(23): 2705–2711. PMID: 27298404. PMCID: PMC5019757.
  17. Moore II RA, **Gerke TA**, Bourgoine D, Eamranond PP. Transition coach program implementation associated with thirty-day readmission rates in a community hospital setting. *Arch Community Med Public Health* 2016; 2(1): 022–026. DOI: 10.17352/2455-5479.000012.
  18. Waniga HM, **Gerke TA**, Shoemaker A, Bourgoine D, Eamranond P. The impact of revised discharge instructions on patient satisfaction. *J Patient Experience* 2016; 3(3): 64–68.
  19. Kelly RS, Sinnott JA, Rider JR, Ebot E, **Gerke TA**, Bowden M, Pettersson A, Loda M, Sesso H, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Vander Heiden M, Mucci LA. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: Results from a nested case-control study. *Cancer Metab* 2016; 4(22): DOI 10.1186/s40170-016-0161-9. PMID: 27980733. PMCID: PMC5142400.
  20. Sinnott JA, Peisch S, Tyekucheva S, **Gerke TA**, Lis RT, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL. Prognostic utility of a new mRNA expression signature of Gleason score. *Clin Cancer Res* 2017; 23(1): 81–87. PMID: 27663590. PMCID: PMC5215643.
  21. Fankhauser CD, Mucci LA, **Gerke TA**. Re: New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8–10 prostate cancer. *Eur Urol* 2017; 72(1): e9–e10. PMID: 28108146.
  22. Pettersson A\*, **Gerke TA\***, Fall K, Pawitan Y, Holmberg L, Giovannucci EL, Kantoff PW, Adami H, Rider JR, Mucci LA. The ABC model of prostate cancer: a conceptual framework for the design and interpretation of prognostic studies. *Cancer* 2017; 123(9): 1490–1496. PMID: 28152172. PMCID: PMC5716345.
  23. Zareba P, Flavin R, Isikbay M, Rider JR, **Gerke TA**, Finn S, Pettersson A, Giunchi F, Unger RH, Andersson SO, Giovannucci EL, Andrén O, Fall K, Fiorentino M, Mucci LA. Perineural invasion and risk of lethal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2017; 26(5): 719–726. PMID: 28062398. PMCID: PMC5413395.
  24. Chen Z, **Gerke TA**, Bird V, Prosperi M. Trends in gene expression profiling for prostate cancer risk assessment: a systematic review. *Biomed Hub* 2017; 2:472146.

25. Ebot E, **Gerke TA**, Labbé D, Sinnott J, Zadra G, Rider J, Tyekucheva S, Wilson K, Kelly R, Shui I, Loda M, Kantoff P, Finn S, Vander Heiden M, Giovannucci E, Brown M, Mucci LA. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. *Cancer* 2017; 123(21): 4130–4138. PMID: 28700821. PMCID: PMC5802874.
26. Mucci LA, Perner CH, Peisch S, **Gerke TA**, Wilson KM. Prostate cancer incidence as an iceberg. *Eur J Epidemiol* 2017; 32(6): 477–479. PMID: 28560536. PMCID: PMC5709244.
27. Stopsack KH, **Gerke TA**, Andrén O, Andersson S, Giovannucci EL, Mucci LA, Rider JR. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. *Carcinogenesis* 2017; 38(8): 806–811. PMID: 28595267. PMCID: PMC6074871.
28. Wang K, Chen X, Bird VY, **Gerke TA**, Manini TM, Prosperi M. Association between age-related reductions in testosterone and risk of prostate cancer – an analysis of patients’ data with prostatic diseases. *Int J Cancer* 2017; 141(9): 1783–1793. PMID: 28699177. PMCID: PMC6169522.
29. Li D, Mai V, **Gerke TA**, Pinney SM, Yaghjian L. Interactions of family history of breast cancer with radiotherapy in relation to the risk of breast cancer recurrence. *J Breast Cancer* 2017; 20(4): 333–339. PMID: 29285037 PMCID: PMC5743992.
30. Pettersson A\*, **Gerke TA\***, Penney KL, Lis R, Stack EC, Pérttega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M. MYC overexpression at the protein and mRNA level and cancer outcomes among men treated with radical prostatectomy for prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2018; 27(2): 201–207. PMID: 29141848 PMCID: PMC5831163.
31. Graff RE, Ahearn TU, Pettersson A, Ebot EM, **Gerke TA**, Penney KL, Wilson KM, Markt S, Perner CH, Gonzalez-Feliciano AG, Song M, Lis R, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, Mucci LA. Height, obesity, and the risk of TM-PRSS2:ERG-defined prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2018; 27(2): 193–200. PMID: 29167279 PMCID: PMC5809280.
32. Jones AA, **Gerke TA**, Striley CW, Whitehead N, Osborne V, Cottler LB. One step at a time: A latent transitional analysis on changes in substance use, exposure to violence, and HIV/AIDS risk behaviors among female offenders. *Am J Crim Just* 2018; 43(3): 471–485. PMID: 30220837.
33. Jones AA, O’Leary CC, Striley CW, **Gerke TA**, Striley CW, Crecelius R, Sullivan J, Cottler LB. Substance use, victimization, HIV/AIDS risk, and recidivism among females in a therapeutic justice program. *J Subst Use* 2018; 23(4): 415–421.
34. Williams V, Awasthi S, Fink A, Pow-Sang J, Park J, **Gerke TA**, Yamoah K. African American Men and prostate cancer specific mortality: A competing risk analysis of a large institutional cohort, 1989–2015. *Cancer Med* 2018; 7(5): 2160–2171. PMID: 29601662. PMCID: PMC5943433.
35. Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, **Gerke TA**, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du S, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud G, Inamoto T, Lee GM, Mucci L, Azuma H, Sweeney CJ, Kantoff P. Synthetic lethality by ATR inhibition in aggressive prostate cancer deficient in male specific histone demethylase KDM5D. *J Clin Investig* 2018; 128(7): 2979–2995. PMID: 29863497. PMCID: PMC6025984.
36. Peeri NC\*, Creed J\*, Anic GM, Olson JJ, LaRocca RV, Chowdhary SJ, Brockman JD, **Gerke TA**, Nabors LB, Egan KM. Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma. *Cancer Epidemiol* 2018; Aug(55): 45–51. PMID: 29777993.

37. Rounbehler RJ, Berglund AE, **Gerke TA**, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin is a prognostic biomarker for poor outcomes among patients with low-grade prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2018; 27(11): 1376–1383. PMID: 30108099. PMCID: PMC6214732.
38. Barber L, **Gerke TA**, Markt S, Peisch S, Wilson K, Ahearn T, Giovannucci E, Parmigiani G, Mucci L. Family history of breast or prostate cancer and prostate cancer risk. *Clin Cancer Res* 2018; 24(23): 5910–5917. PMID: 30082473. PMCID: PMC6279573.
39. Stopsack KH, Ebot EM, Downer MK, **Gerke TA**, Rider JR, Kantoff PW, Mucci LA. Regular aspirin use and gene expression profiles in prostate cancer patients. *Cancer Causes Control* 2018; 29(8): 775–784. PMID: 29915914. PMCID: PMC6298857.
40. Ahearn TU\*, Peisch S\*, Pettersson A, Ebot EM, Zhou K, Graff RE, Sinnott JA, Fazli L, Judson GJ, Bismar TA, Rider JR, **Gerke TA**, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M\*\*, Mucci LA\*\*. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. *Carcinogenesis* 2018; 39(12): 1431–1437. PMID: 30165429. PMCID: PMC6314328.
41. Ren Y, Ay A, **Gerke T**, Kahveci T. Identification of jointly correlated gene sets. *J Bioinform Comput Biol* 2018; 16(5): 1840019-1–23.
42. Wang K, Chen X, **Gerke T**, Bird VY, Ghayee HK, Prosperi M. BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions. *Cancer Med* 2018; 7(10): 5272–5280. PMID: 30207080. PMCID: PMC6198207.
43. Preston MA\*, **Gerke TA**\*, Carlsson SV, Signorello L, Sjoberg DD, Markt SC, Kibel AS, Trinh Q, Steinwandel M, Blot W, Vickers AJ, Lilja H, Mucci LA\*\*, Wilson KM\*\*. Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in black men. *Eur Urol* 2019; 75(3): 399–407. PMID: 30237027. PMCID: PMC6390280.
44. **Gerke TA**, Beltran H, Wang X, Lee G, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low tristetraprolin expression is associated with lethal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2019; 28(3): 584–590. PMID: 30420441.
45. Awasthi A, **Gerke TA**, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee D, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K. Optimizing time-to-treatment to achieve durable biochemical disease control after surgery in prostate cancer - A multi-institutional cohort study. *Cancer Epidemiol Biomarkers Prev* 2019; 28(3): 570–577. PMID: 30413401.
46. Fankhauser CD, **Gerke TA**, Roth L, Sander S, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Beyer J, Hermanns T. Pre-orchietomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment. *J Cancer Res Clin Oncol* 2019; 145(3): 781–785. PMID: 30637464.
47. Awasthi S, **Gerke TA**, Williams VL, Asamoah F, Fink AK, Balkrishnan R, Park JY, Yamoah K. Interrelationship between health insurance status and prostate cancer grade can have critical impact on prostate cancer disease control: A retrospective cohort study. *Cancer Control* 2019; 26(1): 1–9. PMID: 30935222.
48. Yamoah K, Berglund A, Rounbehler R, **Gerke TA**, Awasthi S, Cheng C, Takhar M, Alshalalfa M, Erho N, Klein E, Freedland S, Ross A, Schaeffer E, Trock B, Den R, Cleveland J, Park J, Dhillon J. Distinct transcriptional repertoire of the androgen receptor in ETS

- fusion-negative prostate cancer. *Prostate Cancer Prostatic Dis* 2019; 22(2): 292–302. PMID: 30367117.
49. Jones AA, **Gerke T**, Ennis N, Striley CW, Crecelius R, Sullivan JE, Cottler LB. Order in the court? The association between substance use, exposure to violence, risky sexual behaviors & observed court behaviors among women involved in the criminal justice system. *J Natl Med Assoc* 2019; 111(2): 134–147. PMID: 30409715.
  50. Stopsack KH, **Gerke TA**, Tyekucheva S, Mazzu YZ, Lee GM, Chakraborty G, Abida W, Mucci LA, Kantoff PW. Low expression of the androgen-induced tumor suppressor gene PLZF and lethal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2019; 28(4): 707–714. PMID: 30602500.
  51. Khan NA, Stopsack KH, Allott EH, **Gerke TA**, Giovannucci EL, Mucci LA, Kantoff PW. Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2019; 28(6): 1052–1058. PMID: 30867220.
  52. Echevarria MI, Awasthi S, Cheng C, Berglund AE, Rounbehler RJ, **Gerke TA**, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K. African American-specific gene panel predictive of poor prostate cancer outcome. *J Urol* 2019; 202(2): 247–255. PMID: 31107158.
  53. Mazzu Y, Armenia J, Chakraborty G, Yoshikawa Y, Coggins S, Nandakumar S, **Gerke TA**, Pomerantz M, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee G, Fine S, Bell C, O'Connor E, Long H, Freedman M, Kim B, Kantoff P. A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). *Clin Cancer Res* 2019; 25(14): 4480–4492. PMID: 30996073.
  54. Stopsack KH, Whittaker CA, **Gerke TA**, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. *PNAS* 2019; 116(23): 11390–11395. PMID: 31085648.
  55. Creed JH, Peeri NC, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, **Gerke TA**, Nabors LB, Egan KE. Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. *Sci Rep* 2019; 9(1): 1–7. PMID: 31350461.
  56. Ostrom QT, Egan KM, Nabors LB, **Gerke TA**, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz-Sloan JS, Bondy ML. Glioma risk associated with extent of estimated European genetic ancestry in African-Americans and Hispanics. *Int J Cancer* 2019; 146(3): 739–748. PMID: 30963577.
  57. Creed JH, Aden-Buie G, Monteiro AN, **Gerke TA**. epiTAD: a web application for visualizing chromosome conformation capture data in the context of genetic epidemiology. *Bioinformatics* 2019; 35(21): 4462–4464. PMID: 31099399.
  58. Wang K, **Gerke TA**, Chen X, Prosperi M. Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. *Cancer Med* 2019; 8(17): 7399–7407. PMID: 31595713.
  59. Laajala TD, **Gerke TA**, Tyekucheva S, Costello JC. Modeling genetic heterogeneity of drug response and resistance in cancer. *Curr Opin Syst Biol* 2019; 17: 8–14. PMID: 37736115.

60. **Gerke TA**, Awasthi S, Yamoah K. Biology versus access to care: Relative contribution to racial disparities in prostate cancer remains an open question. *JAMA Oncol* 2019; 5(12): 1809–1810.
61. Allott E, Ebot E, Stopsack K, Gonzalez-Feliciano A, Markt S, Wilson K, Ahearn T, **Gerke TA**, Downer M, Rider J, Freedland S, Lotan T, Kantoff P, Platz E, Loda M, Stampfer M, Giovannucci E, Sweeney C, Finn S, Mucci L. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. *Clin Cancer Res* 2019; 26(5): 1086–1093. PMID: 31754047.
62. Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, Yamoah K, **Gerke TA**. Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk. *Cancer Epidemiol Biomarkers Prev* 2020; 29(1): 246–253. PMID: 31757784.
63. de la Iglesia J, Slebos R, Martin-Gomez L, Wang X, Teer J, Tan AC, **Gerke TA**, Aden-Buie G, Van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel E, Schabath M, Wadsworth J, Caudell J, Harrison L, Wenig B, Conejo-Garcia J, Hernandez-Prera J, Chung C. Effects of tobacco smoking on the tumor immune microenvironment in head and neck squamous cell carcinoma. *Clin Cancer Res* 2020; 26(6): 1474–1485. PMID: 31848186.
64. Khan S\*, Caldwell J\*, Wilson KM, Gonzalez-Feliciano A, Peisch S, Pernar CH, Graff RE, Giovannucci E, Mucci LA, **Gerke TA\*\***, Markt SC\*\*. Baldness and risk of prostate cancer in the Health Professionals Follow-Up Study. *Cancer Epidemiol Biomarkers Prev* 2020; 29(6): 1229–1236. PMID: 32277004.
65. Creed JH, **Gerke TA**, Berglund AE. MatSurv: Survival analysis and visualization in Matlab. *J Open Source Softw*; 5(46): 1830–1834.
66. Creed JH, Smith-Warner SA, **Gerke TA\***, Egan KM\*. A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank. *Eur J Cancer* 2020; Apr;129: 123–131. PMID: 32151942.
67. Brady R, Nagy J, **Gerke TA**, Zhang T, Wang AZ, Zhang J, Gatenby R, Enderling H. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. *Nat Commun* 2020; 11(1): 1750. PMID: 32273504.
68. Barnholtz-Sloan JS, Rollison DE, Basu A, Borowsky AD, Bui A, DiGiovanna J, Garcia-Closas M, Genkinger JM, **Gerke TA**, Induni M, Lacey Jr JV, Mirel L, Permuth JB, Saltz J, Shenkman EA, Ulrich CM, Zheng WJ, Nadaf S, Kibbe WA. Cancer Informatics for Cancer Centers (CI4CC): Building a community focused on sharing ideas and best practices to improve cancer care and patient outcomes. *JCO Clin Cancer Inform* 2020; Feb;4: 108–116. PMID: 32078367.
69. Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, Fiorentino M, Loda M, Mahal B, **Gerke TA**, Preston MA, Mucci LA. Inferior cancer survival in men with localized high-grade prostate cancer but low PSA. *Eur Urol* 2020; 78(4): 637–639. PMID: 32624279.
70. Stopsack KH\*, **Gerke TA\***, Zareba P\*, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M\*\*, Mucci LA\*\*. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. *Carcinogenesis* 2020; 41(7): 904–908. PMID: 32556091.
71. Stopsack KH, Huang Y, Tyekucheva S, **Gerke TA**, Bango C, Elfandy H, Bowden M, Penney K, Roberts T, Parmigiani G, Kantoff P, Mucci L, Loda M. Multiplex immunofluorescence in formalin-fixed paraffin-embedded tumor tissue to identify single cell-level PI3K pathway activation. *Clin Cancer Res* 2020; 26(22): 5903–5913. PMID: 32913135.

72. Yamoah K, Lal P, Awasthi S, Naghavi AO, Rounbehler RJ, **Gerke TA**, Berglund AE, Pow-Sang JM, Schaeffer EM, Dhillon J, Park JY, Rebbeck TR. TMPRSS2-ERG fusion impact anterior tumor location in men with prostate cancer. *Prostate* 2021; 81(2): 109–117. PMID: 33141952.
73. Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia J, Slebos R, Centeno B, Tarasova V, Hallanger-Johnson J, Veloski C, Otto K, Wenig B, Yoder S, Lam C, Park D, Anderson A, Raghunand N, Berglund A, Caudell J, **Gerke TA**, Chung C. Molecular determinants of thyroid nodules with indeterminate cytology and RAS mutations. *Thyroid* 2021; 31(1): 36–49. PMID: 32689909.
74. Cote DJ, Smith-Warner SA, Creed JH, Furtado J, **Gerke TA**, Wang M, Kim Y, Stampfer MJ, Egan KM. Circulating lipids and glioma risk: results from the UK Biobank, Nurses' Health Study, and Health Professionals Follow-Up Study. *Cancer Causes Control* 2021; 32(4): 347–355. PMID: 33484419.
75. McKay RR, Gold T, Zarif JC, Chowdhury-Paulino IM, Friedant A, **Gerke TA**, Grant M, Hawthorne K, Heath E, Huang FW, Jackson MD, Mahal B, Ogbeide O, Paich K, Ragin C, Rencsok EM, Simmons S, Yates C, Vinson J, Kantoff PW, George DJ, Mucci LA. Tackling diversity in prostate cancer clinical trials: A report from the Diversity Working Group of the IRONMAN Registry. *JCO GO* 2021; Apr;7: 495–505. PMID: 33835826.
76. Lin H, Huang P, Chia-Ho C, Tung H, Fang Z, Berglund AE, Chen A, French J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, **Gerke TA**, Dhillon J, Eeles R, Kote-Jarai Z, Muir K, UKGPCS collaborators, Schleutker J, Pashayan N, APCB (Australian Prostate Cancer BioResource), Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw K, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H, PRACTICAL consortium, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions and SNP-interaction polygenic risk score for prediction of prostate cancer aggressiveness. *Sci Rep* 2021; 11(1): 9264. PMID: 33927218.
77. Eschrich SA, Teer JK, Reisman P, Siegel E, Challa C, Lewis P, Fellows K, Malpica E, Carvajal R, Gonzalez G, Cukras S, Betin Montes M, Aden-Buie GA, Avedon M, Manning D, Tan AC, Fridley BL, **Gerke TA**, Van Looveren M, Blake A, Greenman J, Rollison D. Enabling precision medicine in cancer care through a molecular data warehouse: the Moffitt experience. *JCO Clin Cancer Inform* 2021; May;5: 561–569. PMID: 33989014.
78. Niell BL, Augusto B, McIntyre M, Conley CC, **Gerke TA**, Roetzheim R, Garcia J, Vadaparampil S. Distribution of estimated lifetime breast cancer risk among women undergoing screening mammography. *AJR* 2021; 217(1): 48–55. PMID: 33978450.
79. Wang V, Geybels MS, Jordahl KM, **Gerke TA**, Hamid A, Penney KL, Markt SC, Freedman M, Pomerantz M, Lee GM, Rana H, Börnigen D, Rebbeck TR, Huttenhower C, Eeles RA, Stanford JL, PRACTICAL Consortium, Mucci LA, Sweeney CJ. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. *Prostate* 2021; 81(10): 683–693. PMID: 33956343.
80. Cote DJ, Creed JH, Samanic CM, **Gerke TA**, Stampfer MJ, Smith-Warner SA, Egan KM. A prospective study of inflammatory biomarkers and growth factors and risk of glioma in the UK Biobank. *Cancer Epidemiol* 2021; Dec;75: 102043. PMID: 34564026.
81. Stopsack KH, Tyekucheva S, Wang M, **Gerke TA**, Vasselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. *Elife*; 2021 Dec 23; 10:e71265. PMID: 34939926.

82. Yamoah K, Awasthi S, Mahal B, Zhao SG, Grass D, Berglund A, Abraham-Miranda J, **Gerke TA**, Davicioni E, Rounbehler RJ, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Schaeffer E, Freedland S, Spratt D, Den R, Rebbeck TR, Feng F. Novel transcriptomic interactions between immune content and genomic classifier predict lethal outcomes in high-grade prostate cancer. *Eur Urol* 2022; 81(4): 325–330. PMID: 33303244.
83. Mazzu YZ, Liao Y, Nandakumar S, Sjöström M, Jehane LE, Ghale R, Govindarajan B, **Gerke TA**, Lee GS, Luo JH, Chinni SR, Mucci LA, Feng FY, Kantoff PW. Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. *Mol Oncol* 2022; 16(13): 2451–2469. PMID: 34792282.
84. Mazzu YZ, Liao Y, Nandakumar S, Jehane LE, Koche RP, Rajanala SH, Li R, Zhao HY, **Gerke TA**, Chakraborty G, Lee GS, Nanjangud GJ, Gopalan A, Chen Y, Kantoff PW. Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. *Oncogene* 2022; 41(5): 671–682. PMID: 34802033.
85. Mahal BA\*, **Gerke TA\***, Awasthi S, Soule HR, Simons JW, Miyahira A, Halabi S, George D, Platz EA, Mucci LA, Yamoah K. Prostate cancer racial disparities: A systematic review by the Prostate Cancer Foundation Panel. *Eur Urol Oncol* 2022; 5(1): 18–29. PMID: 34446369.
86. Wilson C, Soupir AC, Thapa R, Creed J, Nguyen J, Segura CM, **Gerke TA**, Schildkraut JM, Peres LC, Fridley BL. Tumor immune cell clustering and its association with survival in African American women with ovarian cancer. *PLoS Comput Biol* 2022; 18(3): 1–17. PMID: 35235563.
87. Mucci LA, Vinson J, Gold T, **Gerke TA**, Filipenko J, Green RM, Anderson SG, Badal S, Bjartell A, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odehina FT, Olmos D, Omlin A, Popoola AA, Ragin C, Roberts R, Russnes KM, Waihenya C, Stopsack KH, Hyslop T, Villanti P, Kantoff PW, George DJ, IRONMAN Global Team. *JCO Glob Oncol* 2022; 8: 1–12. PMID: 36332173.
88. Franks J, Caston NE, Elkhanany A, **Gerke TA**, Azuero A, Rocque GB. Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer. *Breast Cancer Res Treat* 2023; 197(3): 673–681. PMID: 36539670.
89. Laajala TD, Sreekanth V, Soupir AC, Creed JH, Halkola AS, Calboli FCF, Singaravelu K, Orman MV, Colin-Leitzinger C, **Gerke TA**, Fridley BL, Tyekucheva S, Costello JC. A harmonized resource of integrated prostate cancer clinical, -omic, and signature features. *Sci. Data* 2023; 10(430): 1–13.
90. D'Agostino McGowan L, **Gerke TA**, Barrett M. Causal inference is not just a statistics problem. *J Stat Data Sci Educ* 2023; In press.

## Preprints

1. **Gerke TA**, Tyekucheva S, Mucci LA, Parmigiani G. Logistic push: a regression framework for partial AUC optimization. *arXiv:1606.06562 [stat.AP]*.  
<https://arxiv.org/abs/1606.06562>.
2. Creed JH, Aden-Buie G, Monteiro AN, **Gerke TA**. epiTAD: a web application for visualizing high throughput chromosome conformation capture data in the context of genetic epidemiology. *bioRxiv* 243840.  
<https://www.biorxiv.org/content/early/2018/12/28/243840>
3. Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, Yamoah K, **Gerke TA**. Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk. *bioRxiv* 604058.  
<https://www.biorxiv.org/content/10.1101/604058v1>

4. Brady R, Nagy J, **Gerke TA**, Zhang T, Wang AZ, Zhang J, Gatenby R, Enderling H. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. bioRxiv 624866. <https://www.biorxiv.org/content/10.1101/624866v1>
5. Stopsack KH, Tyekucheva S, Wang M, **Gerke TA**, Vasselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. bioRxiv 450369. <https://www.biorxiv.org/content/10.1101/2021.06.29.450369v2>
6. Wilson C, Thapa R, Creed J, Nguyen J, Segura CM, **Gerke TA**, Schildkraut J, Peres L, Friedley BL. Statistical framework for studying the spatial architecture of the tumor immune microenvironment. medRxiv 21256104. <https://www.medrxiv.org/content/10.1101/2021.04.27.21256104v1>

#### Book chapters

1. Berglund AE, Putney RM, Creed JH, Aden-Buie G, **Gerke TA**, Rounbehler RJ. Accessible Pipeline for Translational Research Using TCGA: Examples of Relating Gene Mechanism to Disease-Specific Outcomes. In: Markowitz J. (eds) Translational Bioinformatics for Therapeutic Development. Methods in Molecular Biology, vol 2194. Humana, New York, NY, 2021. [https://doi.org/10.1007/978-1-0716-0849-4\\_8](https://doi.org/10.1007/978-1-0716-0849-4_8)

#### Conference papers

1. Tradigo G, Vaccac R, Manini T, Bird V, **Gerke T**, Veltri P, Prosperi M. A new approach to disentangle genetic and epigenetic components on disease comorbidities: studying correlation between genotypic and phenotypic disease networks. Procedia Computer Science 2017; 110: 453–458. In: The 14th International Conference on Mobile Systems and Pervasive Computing (MobiSPC): 2017 Jul 24–26; Leuven, Belgium.
2. Ren Y, Ay A, **Gerke T**, Kahveci T. Searching jointly correlated gene combinations. In: International Conference on Bioinformatics and Computational Biology (BICoB): 2018 Mar 19–21; Las Vegas, NV. Award: Best Paper.

#### Conference presentations

*\* denotes oral presentation, – denotes poster presentation*

– Martin NE, **Gerke TA**, Loda MF, Stampfer MJ, Finn S, Rider JR, Mucci LA. Tumor adiponectin signaling underlies the association between obesity and lethal outcome in prostate cancer. In: American Association for Cancer Research Annual Meeting: 2012 Mar 31–Apr 4; Chicago, IL.

\* Zareba P, Pettersson A, **Gerke TA**, Fiorentino M, Flavin R, Rider JR, Giovannucci EL, Finn S, Loda MF, Mucci LA. Immunohistochemical expression of BRCA1 and prostate cancer progression in a large radical prostatectomy cohort. In: 32nd Congress of the Société Internationale d’Urologie: 2012 Sep 30–Oct 4; Fukuoka, Japan.

– Shui IM, Lindström S, **Gerke TA**, Kraft P. Prostate cancer risk variants and disease progression in the NCI Breast and Prostate Cancer Cohort Consortium. In: Proceedings of the AACR Special Conference on Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment: 2012 Nov 11–14; Hollywood, FL.



\* **Gerke TA**, Fiorentino M, Choudhury D, Pettersson A, Zareba P, Kantoff P, Loda MF, Finn S, Mucci LA. Molecular markers associated with altered BRCA1 expression in prostate cancer. In: Sixth Annual Prostate Cancer Program Retreat: 2013 Mar 18-20; Fort Lauderdale, FL.

– Ahearn TU, Pettersson A, Stack EC, Ma J, **Gerke TA**, Meisner A, Pollak MN, Finn S, Stampfer MJ, Loda M, Giovannucci EL, Mucci LA. The IGF/insulin signaling axis TMRSS2: ERG and prostate cancer survival. In: American Association for Cancer Research Annual Meeting: 2013 Apr 6-10; Washington, DC.

– Schwartzman A, Kachouie NN, Huybers P, **Gerke TA**. Spatiotemporal estimation of mountain glacier retreat. In: American Statistical Association Conference on Statistical Practice: 2014 Feb 20-22; Tampa, FL.

– Preston M, Batista J, Carlsson S, **Gerke T**, Dahl D, Feldman A, Gann P, Vickers A, Stampfer M, Mucci L. Prostate-specific antigen (PSA) levels in men <60 years of age predicts lethal prostate cancer. In: American Urological Association Annual Meeting: 2014 May 16-21; Orlando, FL.

– **Gerke T**, Tyekucheva S, Penney K, Sweeney C, Lis R, Nuttall I, Loda M, Stampfer M, Parmigiani G, Mucci L. Discovering a gene expression signature of prostate cancer prognostication by focusing on indolent tumors. In: American Urological Association Annual Meeting: 2014 May 16-21; Orlando, FL.

– Peisch SF, **Gerke T**, Wilson KM, Giovannucci EL, Signorello LB, Mucci LA. Racial disparities in prostate cancer: Estimating the role of diet, lifestyle, and genetic factors among African-American and Caucasian-American men. In: Proceedings of the Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research: 2014 Sep 27-Oct 1; New Orleans, LA.

\* **Gerke T**. Bioinformatics 101: Big data's role in addressing prostate cancer disparities. In: The Third Biennial Science of Global Prostate Cancer Disparities in Black Men: 2014 Nov 5-8; Montego Bay, Jamaica.

\* **Gerke T**, Peisch SF, Wilson KM, Giovannucci EL, Signorello LB, Mucci LA. Racial disparities in prostate cancer: Estimating the role of diet, lifestyle, and genetic factors among African-American and European-American men. In: The Third Biennial Science of Global Prostate Cancer Disparities in Black Men: 2014 Nov 5-8; Montego Bay, Jamaica.

– **Gerke T**, Tyekucheva S, Penney K, Sweeney C, Lis R, Sesso H, Nuttall E, Loda M, Stampfer M, Parmigiani G, Mucci L. Discovery and validation of a 30-gene expression signature to identify prostate cancer patients who are candidates for active surveillance. In: Genitourinary Cancers Symposium: 2015 Feb 26-28; Orlando, FL.

– Kelly RS, Sinnott JA, Rider JR, Ebot E, **Gerke TA**, Penney KL, Bowden M, Pettersson A, Loda M, Stampfer M, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Vander Heiden M, Mucci LA. Tumor metabolism as a driver of lethal prostate cancer. In: AACR Special Conference, Metabolism and Cancer: 2015 June 7-10; Bellevue, WA.

– Ebot EM, **Gerke T**, Tyekucheva S, Labbé DP, Zadra G, Kelly RS, Bowden M, Rider JR, Wilson KM, Martin NE, Brown M, Vander Heiden MG, Giovannucci EL, Loda M, Mucci LA. Identifying obesity-linked gene expression changes in prostate cancer. In: AACR Special Conference, Metabolism and Cancer: 2015 June 7-10; Bellevue, WA.

- Stopsack KH, **Gerke T**, Cerhan JR, Mucci LA, Rider JR. Increased cholesterol synthesis via squalene monooxygenase to predict lethal prostate cancer. In: Genitourinary Cancers Symposium: 2016 Jan 7-9; San Francisco, CA.
- Wilson KM, **Gerke T**, Ebot E, Sinnott JA, Rider JR, Mucci LA. Differential gene expression in prostate tissue according to vasectomy. In: Genitourinary Cancers Symposium: 2016 Jan 7-9; San Francisco, CA.
- Barber LE, **Gerke T**, Markt SC, Parmigiani G, Mucci LA. A family affair: Prostate cancer risk and family history of breast or prostate cancer. In: American Association for Cancer Research Annual Meeting: 2016 Apr 16-20; New Orleans, LA.
- Stopsack KH, **Gerke T**, Mucci LA, Rider JR. PTEN expression, cholesterol metabolism, and lethal prostate cancer. In: American Association for Cancer Research Annual Meeting: 2016 Apr 16-20; New Orleans, LA.
- Rider JR, Wilson KM, **Gerke T**, Ebot E, Sinnott JA, Mucci LA. Differential gene expression in prostate tissue according to sexual behaviors. In: American Urological Association Annual Meeting: 2016 May 6-10; San Diego, CA.
- Preston M, Wilson K, **Gerke T**, Carlsson S, Sjoberg D, Kibel A, Trinh Q, Signorello L, Steinwandel M, Vickers A, Lilja H, Mucci L. Baseline prostate-specific antigen (PSA) levels in midlife predict total and aggressive prostate cancer in African-American men. In: American Urological Association Annual Meeting: 2016 May 6-10; San Diego, CA.
- \* Stopsack KH, **Gerke T**, Mucci LA, Rider JR. Prostate cancer prognostication based on an actionable metabolic pathway. In: AACR Improving Cancer Risk Prediction for Prevention and Early Detection: 2016 Nov 16-19; Orlando, FL.
- Fankhauser C, Wilson K, Rider J, Penney K, Peisch S, Fiorentino M, Kantoff P, Moch H, Mucci L, **Gerke T**. Do more granular Gleason categorizations lead to better prognostic accuracy over time? In: Annual European Association of Urology Congress: 2017 Mar 24-28; London, England.
- **Gerke T**, Börnigen D, Beltran H, Tyekucheva S, Huttenhower C, Lee G, Lotan T, Trock B, Mucci L, Sweeney C. Loss of the tumor suppressor Zinc Finger Protein-36 and risk of lethal prostate cancer. In: American Association for Cancer Research Annual Meeting: 2017 Apr 1-5; Washington, DC.
- Berglund AE, **Gerke T**, Awasthi S, Grass GD, Park HY, Cleveland JL, Park JY, Yamoah K, Rounbehler RJ. Tristetraprolin is a prognostic biomarker for biochemical recurrence in low Gleason score patients. In: American Association for Cancer Research Annual Meeting: 2017 Apr 1-5; Washington, DC.
- Ebot E, Isikbay M, **Gerke T**, Ahearn TU, Kelly RS, Tyekucheva S, Pettersson A, Penney KL, Mucci L. Gene expression profiling of prostate tissue identifies biological pathways associated with TMPRSS2:ERG gene fusion. In: American Association for Cancer Research Annual Meeting: 2017 Apr 1-5; Washington, DC.
- Preston M, Downer MK, **Gerke T**, Carlsson S, Sesso H, Kibel A, Trinh Q, Lilja H, Vickers A, Wilson K, Mucci L. Prostate-specific antigen (PSA) levels in men aged 60 to 70 and development of lethal prostate cancer over 30 years: Implications for risk-stratified screening. In: American Urological Association Annual Meeting: 2017 May 12-16; Boston, MA.

- Creed JH, **Gerke T**, Monteiro A. EpiTAD Viewer: A Software Application for Visualizing and Contextualizing HI-C Data in Genetic Epidemiology. In: Moffitt Scientific Symposium: 2017 May 4; Tampa, FL. Award: Population Science Poster Winner.
- Sweeney C, **Gerke T**, Beltran H, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross A, Mucci LA, Trock BJ. Association of loss of tumor suppressor ZFP36 with lethal prostate cancer. In: ASCO Annual Meeting: 2017 Jun 2-6; Chicago, IL.
- Sweeney CJ, Geybels M, Markt SC, Wang V, Penney K, **Gerke T**, Pomerantz MM, Lee GS, Nitsch D, Huttenhower C, Mucci L. 821PA polymorphism in the promoter of the FRAS1 gene is associated with metastatic prostate cancer. In: European Society for Medical Oncology Congress: 2017 Sep 8-12; Madrid, Spain.
- Yuan ZM, Yang GQ, Oliver DE, Takhar M, Erho NG, Berglund AE, Park J, Rounbehler RJ, **Gerke T**, Jordan J, Davicioni E, Torres-Roca JF, Mulé JJ, Rayford W, Yamoah K. Integrative characterization of the 12-chemokine gene expression signature in prostate cancer. In: Proceedings of the American Society for Radiation Oncology (ASTRO): 2017 Sep 24-27; San Diego, CA.
- Yamoah K, Rounbehler RJ, Takhar M, **Gerke T**, Park J, Awasthi S, Erho NG, Davicioni E, Cleveland JL, Berglund AE. Distinct AR-dependent transcriptional program in TMPRSS2-ERG fusion negative tumors in African-American men with prostate cancer. In: Proceedings of the American Society for Radiation Oncology (ASTRO): 2017 Sep 24-27; San Diego, CA.
- \* **Gerke T**. Prognostic indicators in prostate cancer. In: New Frontiers in Urologic Oncology: 2017 Nov 2-4; Clearwater, FL.
- Ostrom Q, Egan K, Nabors B, Amos C, Armstrong G, Bernstein J, Chowdhary S, Claus E, Eckel-Passow J, **Gerke T**, Houlston R, Il'yasova D, Jenkins R, Johansen C, Lachance D, Lai R, LaRocca R, Lau C, Merrell R, Olson JJ, Olson S, Sadetzki S, Schildkraut J, Shete S, Thompson R, Wrensch M, Wiencke J, Melin B, Bondy M, Barnholtz-Sloan J. Evaluating glioma risk associated with extent of European admixture in African-Americans and Latinos. In: Society for Neuro-Oncology (SNO) Annual Meeting: 2017 Nov 16-19; San Francisco, CA.
- **Gerke T**, Tyekucheva S, Creed JH, Penney KL, Sinnott JA, Ebot E, Berglund AE, Loda M, Stampfer MJ, Kraft P, Parmigiani G, Mucci LA. All happy families are alike: Transcriptomic homogeneity in indolent prostate tumors is a useful prognostic biomarker. In: Prostate Cancer: Advances in Basic, Translational, and Clinical Research (AACR Special Conference): 2017 Dec 2-5; Orlando, FL.
- Mazzu YZ, **Gerke T**, Chakraborty G, Armenia J, Atiq MO, Komura K, Yoshikawa Y, Lee GS, Mucci LA, Kantoff PW. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer. In: Genitourinary Cancers Symposium: 2018 Feb 8-10; San Francisco, CA.
- Stopsack KH, **Gerke T**, Tyekucheva S, Mucci LA, Kantoff PW. Regulation of the tumor suppressor PLZF and prostate cancer prognosis. In: Genitourinary Cancers Symposium: 2018 Feb 8-10; San Francisco, CA.
- Creed JH, Berglund AE, Yamoah KJ, **Gerke TA**. Ancestry informative eQTLs in prostate tumor tissue: implications for observed cancer disparities. In: USF Health Research Day: 2018 Feb 23; Tampa, FL.

- Nwogu O, Creed JH, Egan KM, **Gerke TA**. Leveraging eQTL analysis to identify genes associated with glioblastoma multiforme survival. In: USF Health Research Day: 2018 Feb 23; Tampa, FL.
- Ostrom QT, Egan KM, Nabors L, **Gerke T**, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JKW, Amos CI, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai R, Merrell RT, Olson SH, Sadetzki S, Schildkraut J, Shete S, Houlston RS, Jenkins RB, Melin B, Bondy ML, Barnholtz-Sloan JS. Evaluating glioma risk associated with extent of European admixture in African-Americans and Latinos. In: American Association for Cancer Research Annual Meeting: 2018 Apr 14-18; Chicago, IL.
- Wang K, Chen X, **Gerke T**, Bird V, Prosperi M. Getting rid of obesity in middle-to-late adulthood relates to lower prostate cancer risk: Another piece of evidence supporting the “rapid testosterone reduction theory.” In: American Association for Cancer Research Annual Meeting: 2018 Apr 14-18; Chicago, IL.
- Khan NA, Stopsack KH, Allott EH, **Gerke T**, Giovannucci EL, Mucci LA, Kantoff PW. Intratumoral CYP27A1 expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer. In: American Association for Cancer Research Annual Meeting: 2018 Apr 14-18; Chicago, IL.
- Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, **Gerke T**, Coggins SA, Qiu X, Atiq M, Stopsack K, Lee GS, Long HW, Kim B, Freedman ML, Pomerantz MM, Mucci LA, Kantoff PW. Targeting poor-prognosis subtypes of prostate cancer by inhibition of DNA repair gene ribonucleotide reductase small subunit M2. In: American Association for Cancer Research Annual Meeting: 2018 Apr 14-18; Chicago, IL.
- Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, **Gerke T**, Atiq M, Stopsack K, Komura K, Lee GS, Mucci LA, Kantoff PW. Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression. In: American Society of Clinical Oncology Annual Meeting: 2018 Jun 1-5; Chicago, IL.
- Berglund A, Putney R, Creed J, Aden-Buie G, **Gerke T**, Rounbehler R. Accessible pipeline for translational research using TCGA: Tristetraprolin as an example relating gene mechanism to a disease specific outcomes. In: TCGA Legacy: Multi-Omic Studies in Cancer: 2018 Sep 27-29; Washington, DC.
- Laajala TD, Aden-Buie G, **Gerke T**, Creed J, Berglund A, Stopsack K, Cramer SD, Tyekucheva S, Aittokallio T, Costello JC. Identifying genetic interactions that drive aggressive prostate cancer using an ensemble of penalized Cox regression models. In: AACR Convergence: Artificial Intelligence, Big Data, and Prediction in Cancer: 2018 Oct 14-17; Newport, RI.
- Echevarria M, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, **Gerke T**, Takhar M, Davicioni E, Erho NG, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park J, Yamoah K. Novel genomic biomarker panel predictive of aggressive disease in African American men with prostate cancer. In: Proceedings of the American Society for Radiation Oncology (ASTRO): 2018 Oct 21-24; San Antonio, TX.
- Awasthi S, Creed JH, Williams V, **Gerke TA**, Yamoah K. Treatment related race disparities in long term survival among very low risk prostate cancer patients. In: 43rd Annual Society of Preventive Oncology Conference: 2019 Mar 10-12; Tampa, FL.
- Creed JH, Awasthi S, Yamoah KJ, **Gerke TA**. Gleason grade progresses in a race-dependent

- manner. In: 43rd Annual Society of Preventive Oncology Conference: 2019 Mar 10–12; Tampa, FL.
- Berger A, Aden-Buie G, Kibel AS, Mucci LA, Penney K, Wilson K, **Gerke TA**, Preston M. Prostate-specific antigen (PSA) levels in men 60 to 70 years of age predict aggressive prostate cancer in the PLCO cancer screening trial: Implications for risk-stratified screening. In: European Association of Urology Congress: 2019 Mar 15–19; Barcelona, Spain.
  - Yamoah K, Awasthi S, Lal P, Naghavi AO, Mahajan S, Park JY, Rounbehler R, **Gerke TA**, Berglund A, Pow-Sang J, Dhillon J, Rebbeck TR. Clinical implications of tmprss2-erg fusion and tumor location in prostate cancer. In: AACR Annual Meeting: 2019 Mar 29–Apr 3; Atlanta, GA.
  - Markt SC, Ebot E, Cheng I, Wilkens L, Shafi A, Knudsen K, Penney K, Mucci L, **Gerke TA**. Circadian clock gene expression and lethal prostate cancer outcomes. In: AACR Annual Meeting: 2019 Mar 29–Apr 3; Atlanta, GA.
  - \* Stopsack KH, Whittaker CA, **Gerke TA**, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. In: AACR Annual Meeting: 2019 Mar 29–Apr 3; Atlanta, GA.
  - \* Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, **Gerke TA**. Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk. In: AACR Annual Meeting: 2019 Mar 29–Apr 3; Atlanta, GA.
  - Aden-Buie G, Creed JH, **Gerke TA**. A web application and software package for analysis and exploration of the FCDS Florida Cancer Registry Data. In: Moffitt Scientific Symposium: 2019 May 1–2; Tampa, FL.
  - \* Creed JH, **Gerke TA**. Global ancestry estimation and data repository for the TCGA pan-cancer resource. In: Moffitt Scientific Symposium: 2019 May 1–2; Tampa, FL.
  - \* **Gerke TA**, Genkinger J, Zheng W. Data integration and availability through CCSG cores (panel discussion). In: Cancer Informatics for Cancer Centers (Ci4CC) Fall Workshop and Symposium: 2019 Oct 14–16; Napa, CA.
  - Carvajal R, Gonzalez-Calderon G, Betin-Montes M, Gai-Cherry M, Creed JH, **Gerke TA**, Eschrich S, Berglund A. Patient timelines for research-oriented exploration of longitudinal cancer patient data: PT Explorer. In: American Medical Informatics Association (AMIA) Annual Symposium: 2019 Nov 16–20; Washington, DC. Award: Distinguished poster.
  - \* **Gerke TA**. UnicoRns are real. In: rstudio::conf 2020 Jan 27–28; San Francisco, CA.
  - Ceraolo C, **Gerke TA**, Zareba P, Pettersson A, Stopsack KH, Chowdhury D, Ebot EM, Flavin R, Finn SP, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, Mucci LA. Tumor protein expression of BRCA1 and development of lethal prostate cancer. In: Genitourinary Cancers Symposium: 2020 Feb 13–15; San Francisco, CA.
  - \* Creed JH, **Gerke TA**. mediator: An R package for causal mediation analysis. In: 2020 Statistical Practice in Cancer Conference: 2020 February 28; Tampa, FL.
  - Yamoah K, Awasthi S, Mahal B, Zhao SG, Abraham-Miranda J, **Gerke TA**, Davicioni E, Rounbehler RJ, Berglund AE, Grass DG, Park JY, Pow-Sang JM, Fernandez D, Jain RK, Scha-

effe EM, Freedland S, Spratt DE, Den RB, Kohli M, Rebbeck TR, Fang FY. Immunogenomic landscape of grade group 5 prostate cancer predicts risk of lethal outcomes and may inform treatment response. In: AACR Annual Meeting: 2020 Apr 27–28 and Jun 22–24; Philadelphia, PA.

\* **Gerke TA**. CONSORT Diagrams in R with ggconsort. In: R/Medicine 2021 Aug 24–27; Virtual.

### Invited seminars

- 2009 A method for resolving ties in asymptotic relative efficiency. Undergraduate Research Symposium, University of Florida.
- 2010 Spatial design and geometry with applications in environmental statistics. Department of Biostatistics Summer Project Presentation Series, Harvard School of Public Health.
- 2011 Estimation of mountain glacier retreat via analysis of satellite imagery. Environmental Statistics Seminar Series, Harvard School of Public Health.
- 2012 Gene expression data management and analysis pipeline: an applied example. Bioinformatics Working Group, Channing Division of Network Medicine.
- 2012, 2013 IRB panels and ethics in human subjects research. Undergraduate Seminar in Ethics, Values, and Diversity, Northeastern University.
- 2013 Epidemiologic methods for case-control studies of gene expression. Cancer Epidemiology Fellows Seminar, Harvard School of Public Health.
- 2015 Understanding molecular cancer research. Alachua County Prostate Cancer Alliance.
- 2015 Handling big data in R. Gainesville R Users Group; Gainesville, FL.
- 2015 Building clinically useful prognostic models from high-dimensional feature spaces by focusing on partial AUC. University of Florida Department of Statistics Seminar Series.
- 2015 Computational approaches to the challenge of molecular discovery in prostate cancer. University of Florida Health Cancer Center Seminar Series.
- 2016 Designing molecular epidemiology studies. University of Florida Biostatistics, Epidemiology and Research Design (BERD) Studio.
- 2017 Confounding. Moffitt Cancer Center Population Science Seminar Series for Research Staff.
- 2018 Estimating the effectiveness of non-randomized treatment regimes with the parametric g-formula. Integrated Mathematical Oncology / Physical Sciences in Oncology Center Seminar Series; Moffitt Cancer Center.
- 2018 Data acquisition, management, sharing, and ownership. Responsible Conduct of Research Series; Moffitt Cancer Center.
- 2019 Tired::wired – R workflow lessons from rstudio::conf 2019. Tampa R Users Group; Tampa, FL.
- 2019 Overcooked models: mixing prediction, explanation, confounders, and mediators. Interdisciplinary Data Sciences Consortium Seminar Series; University of South Florida.
- 2020 Job market analysis for the R data scientist. Tampa R Users Group; Tampa, FL.

### Software development

Barr CD, **Gerke TA**, Diez DM. voronoi: Methods and applications related to Voronoi tessellations. R package 2011; version 1.0.

Creed JH, Aden-Buie G, Monteiro AN, **Gerke TA**. epiTAD: A web application for visualizing high throughput chromosome conformation capture data in the context of genetic epidemiology, <https://apps.gerkelab.com/epiTAD/>. R Shiny Application 2019; latest development version <https://www.gerkelab.com/project/epitad/>.

Creed JH, **Gerke TA**, Berglund AE. MatSurv: Survival analysis and visualization in Matlab. MatLab package 2019; latest development version <https://github.com/aeberg1/MatSurv>.

Creed JH, Aden-Buie G, **Gerke TA**. ShinyDAG: A web application for building, analyzing, and visualizing directed acyclic graphs (DAGs), <https://apps.gerkeLab.com/shinyDAG/>. R Shiny Application 2019; latest development version <https://github.com/GerkeLab/ShinyDAG>.

Creed JH, Aden-Buie G, **Gerke TA**. mediator: An R package for implementing causal mediation analyses. R Package 2019; latest development version <https://github.com/GerkeLab/mediator>.

Stopsack KH, **Gerke TA**. batchtma R package: Methods to address batch effects. R Package 2021; latest development version <https://stopsack.github.io/batchtma/>.

**Gerke TA**, Aden-Buie G. ggconsort R package: CONSORT diagrams with ggplot. R Package 2021; latest development version <https://github.com/tgerke/ggconsort>.

Stopsack KH, **Gerke TA**. risks R package: Estimate risk ratios and risk differences using regression. R Package 2023; latest development version <https://stopsack.github.io/risks/>.

### Other education

Frontiers in Causal Inference Workshop: 2012 March 23-24; Harvard University, Cambridge, MA.

AACR Workshop on Integrative Molecular Epidemiology: 2016 August 5-9; Boston, MA.

What They Forgot to Teach You About R Workshop: rstudio::conf 2019 January 15-16; Austin, TX.

Flatiron Academic Scholars Program: 2020 December 9; New York, NY.

Deep Learning with Keras and TensorFlow in R Workshop: rstudio::conf 2020 January 27-28; San Francisco, CA.

Snowflake Fundamentals: 2020 September 21-24; Tampa, FL (virtual Snowflake-led training).